Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Provention Bio - Stock

Provention Bio Stock

PRVB
US74374N1028
A2JRLW

Price

24.98
Today +/-
+0
Today %
+0 %
P

Provention Bio Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Provention Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Provention Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Provention Bio’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Provention Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Provention Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Provention Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Provention Bio’s growth potential.

Provention Bio Revenue, EBIT and net profit per share

DateProvention Bio RevenueProvention Bio EBITProvention Bio Net Income
2029e1.12 B undefined0 undefined0 undefined
2028e958.8 M undefined0 undefined682.54 M undefined
2027e733.38 M undefined516.07 M undefined532.69 M undefined
2026e504.9 M undefined126.33 M undefined76.37 M undefined
2025e416.71 M undefined67.07 M undefined82.18 M undefined
2024e133.08 M undefined-70.65 M undefined-58.25 M undefined
2023e44.72 M undefined-159.88 M undefined-180.4 M undefined
202212.9 M undefined-128.16 M undefined-113.57 M undefined
20211.4 M undefined-115.58 M undefined-114.43 M undefined
20200 undefined-99.69 M undefined-98.58 M undefined
20190 undefined-44.37 M undefined-43.29 M undefined
20180 undefined-26.81 M undefined-26.75 M undefined
20170 undefined-9.14 M undefined-9.48 M undefined
20160 undefined-160,000 undefined-160,000 undefined

Provention Bio Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20162017201820192020202120222023e2024e2025e2026e2027e2028e2029e
0000000.010.040.130.420.50.730.961.12
------1,100.00266.67202.27212.7821.1545.4430.7016.81
------100.00-------
000000120000000
0-9-26-44-99-115-128-159-706712651600
------11,500.00-1,066.67-361.36-52.6316.1125.0070.40--
0-9-26-43-98-114-113-180-5882765326820
--188.8965.38127.9116.33-0.8859.29-67.78-241.38-7.32600.0028.20-
33.8833.8833.8840.7552.4663.174.720000000
- - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Provention Bio Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Provention Bio is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Provention Bio provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Provention Bio's financial health and stability.

Assets

Provention Bio's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Provention Bio must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Provention Bio after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Provention Bio's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
0-9-26-43-98-114-113
0000001,000
0000000
00-148617
0365262438
0000000
0000000
0-4-22-36-76-95-75
0000-100
000-4625-31-88
000-4626-30-87
0000000
00000023
0265962114102105
0265962114102129
-------
0000000
02136-1963-24-34
0-4.88-22.64-36.07-77.45-96.35-76.2
0000000

Provention Bio stock margins

The Provention Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Provention Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Provention Bio.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Provention Bio's sales revenue. A higher gross margin percentage indicates that the Provention Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Provention Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Provention Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Provention Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Provention Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Provention Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Provention Bio Margin History

Provention Bio Gross marginProvention Bio Profit marginProvention Bio EBIT marginProvention Bio Profit margin
2029e96.03 %0 %0 %
2028e96.03 %0 %71.19 %
2027e96.03 %70.37 %72.63 %
2026e96.03 %25.02 %15.13 %
2025e96.03 %16.09 %19.72 %
2024e96.03 %-53.08 %-43.77 %
2023e96.03 %-357.52 %-403.41 %
202296.03 %-993.88 %-880.69 %
202196.03 %-8,285.16 %-8,203.01 %
202096.03 %0 %0 %
201996.03 %0 %0 %
201896.03 %0 %0 %
201796.03 %0 %0 %
201696.03 %0 %0 %

Provention Bio Stock Sales Revenue, EBIT, Earnings per Share

The Provention Bio earnings per share therefore indicates how much revenue Provention Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Provention Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Provention Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Provention Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Provention Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Provention Bio Revenue, EBIT and net profit per share

DateProvention Bio Sales per ShareProvention Bio EBIT per shareProvention Bio Earnings per Share
2029e11.81 undefined0 undefined0 undefined
2028e10.12 undefined0 undefined7.2 undefined
2027e7.74 undefined0 undefined5.62 undefined
2026e5.33 undefined0 undefined0.81 undefined
2025e4.4 undefined0 undefined0.87 undefined
2024e1.4 undefined0 undefined-0.61 undefined
2023e0.47 undefined0 undefined-1.9 undefined
20220.17 undefined-1.72 undefined-1.52 undefined
20210.02 undefined-1.83 undefined-1.81 undefined
20200 undefined-1.9 undefined-1.88 undefined
20190 undefined-1.09 undefined-1.06 undefined
20180 undefined-0.79 undefined-0.79 undefined
20170 undefined-0.27 undefined-0.28 undefined
20160 undefined-0 undefined-0 undefined

Provention Bio business model

Provention Bio Inc is a US biotechnology company specializing in the development of preventive therapies for autoimmune diseases and other chronic conditions. The company was founded in 2016 by a group of experienced biotech managers and has its headquarters in Oldwick, New Jersey. The history of Provention Bio begins with the recognition that many current treatments for autoimmune diseases such as type 1 diabetes, celiac disease, and lupus only aim to treat the symptoms of the disease rather than addressing their causes. Therefore, the company is committed to developing innovative and preventive therapies that directly target the causes of autoimmune diseases. Provention Bio's business model is based on sourcing and developing new therapies through to commercialization. The company is dedicated to early-stage research and development and works closely with academic institutions, government agencies, and other companies to achieve its goals. Additionally, Provention Bio invests in clinical trials to prove the efficacy of its therapies and ensure their approval by regulatory authorities. The various divisions of Provention Bio encompass some of the most important autoimmune diseases currently lacking effective cures. These include type 1 diabetes, celiac disease, lupus, MS, and other rare autoinflammatory diseases. Provention Bio's products aim to regulate the immune system and enhance the body's self-healing by influencing biological processes. One of Provention Bio's key products is Teplizumab, a preventive medication for the treatment of type 1 diabetes. The company has acquired the exclusive global rights to this medication, relying on promising results from its clinical trials. Since its FDA approval in 2021, the medication has filled an important market need. Additionally, Provention Bio has several other potential therapies in its pipeline. Among them is PRV-3279, a medication specifically developed for the treatment of celiac disease, currently in phase 2 clinical trials. Additionally, Teplizumab is being investigated for use in other autoimmune diseases such as lupus and MS. The goal of Provention Bio is to positively impact the quality of life and health of millions of people worldwide. The company is working hard to develop innovative preventive therapy approaches that focus on the causes of autoimmune diseases rather than just treating the symptoms. In doing so, Provention Bio is a significant addition to the wide range of existing treatment options by significantly expanding therapeutic choices. In summary, Provention Bio Inc is considered an emerging biotechnology company with great potential in the preventive treatment of autoimmune diseases. The company has a promising pipeline of therapies that have the potential to improve the lives of millions of people worldwide. The company aims to develop preventive and effective therapies that directly address the causes of autoimmune diseases. Provention Bio is one of the most popular companies on Eulerpool.com.

Provention Bio SWOT Analysis

Strengths

Provention Bio Inc has a strong and experienced management team with a deep understanding of the biotechnology industry. This expertise enables them to make informed decisions and navigate the complex regulatory environment.

The company's innovative pipeline includes several promising drug candidates in various stages of development. This diversified portfolio reduces the risk associated with relying on a single product.

Weaknesses

Provention Bio Inc heavily relies on external funding to support its research and development activities. Any delays or difficulties in securing funding could hinder the company's ability to advance its pipeline and bring products to market.

As a relatively young biotech company, Provention Bio Inc has limited financial resources compared to larger competitors. This financial constraint may restrict the company's ability to fully capitalize on market opportunities.

Opportunities

The increasing demand for effective treatments in chronic inflammatory diseases provides Provention Bio Inc with a significant market opportunity. The company's drug candidates targeting these diseases have the potential to address unmet medical needs.

The evolving regulatory landscape, with a greater focus on expedited review and approval processes, presents an opportunity for Provention Bio Inc to accelerate the development and commercialization of its drugs.

Threats

Competition in the biotechnology industry is intense, with numerous established players and emerging startups. Provention Bio Inc must stay ahead of its competitors by continually innovating and demonstrating the superiority of its products.

Failure to meet regulatory requirements or obtain necessary approvals can pose a significant threat to Provention Bio Inc's ability to bring its drug candidates to market. Delays or rejections in the regulatory process can result in substantial setbacks and increased costs.

Provention Bio valuation based on historical P/E ratio, EBIT, and P/S ratio.

Provention Bio shares outstanding

The number of shares was Provention Bio in 2023 — This indicates how many shares 74.723 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Provention Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Provention Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Provention Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Provention Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Provention Bio.

Provention Bio Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2022-0.47 -0.45  (3.78 %)2022 Q4
9/30/2022-0.43 -0.34  (21.11 %)2022 Q3
6/30/2022-0.51 -0.46  (9.29 %)2022 Q2
3/31/2022-0.48 -0.35  (26.76 %)2022 Q1
12/31/2021-0.46 -0.41  (11.24 %)2021 Q4
9/30/2021-0.52 -0.43  (18.03 %)2021 Q3
6/30/2021-0.53 -0.46  (13.55 %)2021 Q2
3/31/2021-0.47 -0.52  (-10.03 %)2021 Q1
12/31/2020-0.52 -0.58  (-12.6 %)2020 Q4
9/30/2020-0.44 -0.56  (-28.53 %)2020 Q3
1
2

Provention Bio Stock Shareholders

%
Name
Stocks
Change
Date
5.70 % Adage Capital Management, L.P.5,398,8252,879,5682/9/2023
5.09 % BlackRock Institutional Trust Company, N.A.4,823,128487,99312/31/2022
4.35 % The Vanguard Group, Inc.4,124,924528,63812/31/2022
2.71 % Leon (Francisco)2,573,00002/13/2023
2.71 % Palmer (Ashleigh)2,570,05002/13/2023
12.53 % Sessa Capital11,879,023-3,000,0001/18/2023
1.64 % State Street Global Advisors (US)1,558,238263,81312/31/2022
1.39 % Geode Capital Management, L.L.C.1,322,189125,39212/31/2022
1.21 % D. E. Shaw & Co., L.P.1,143,3001,038,75712/31/2022
1.18 % VR Adviser, LLC1,118,653012/31/2022
1
2
3
4
5
...
10

Provention Bio Executives and Management Board

Mr. Jason Hoitt44
Provention Bio Chief Commercial Officer
Compensation 5.6 M
Mr. Thierry Chauche46
Provention Bio Chief Financial Officer
Compensation 1.87 M
Dr. Francisco Leon50
Provention Bio Co-Founder, Chief Scientific Officer (since 2017)
Compensation 1.74 M
Mr. Ashleigh Palmer59
Provention Bio President, Chief Executive Officer, Co-Founder, Director (since 2016)
Compensation 1.57 M
Dr. Eleanor Ramos65
Provention Bio Chief Medical Officer
Compensation 1.28 M
1
2
3
4

Provention Bio Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
MacroGenics - Stock
MacroGenics
SupplierCustomer0,690,830,890,190,450,45
Precigen - Stock
Precigen
SupplierCustomer0,420,850,920,190,490,63
Johnson & Johnson - Stock
Johnson & Johnson
SupplierCustomer0,26-0,21-0,68-0,44-0,40-0,77
AGC - Stock
AGC
SupplierCustomer0,010,04-0,16-0,03-0,02-0,84
Huadong Medicine A - Stock
Huadong Medicine A
SupplierCustomer-0,37-0,50--0,320,22-0,60
Amgen - Stock
Amgen
SupplierCustomer-0,44-0,71-0,15-0,07-0,060,23
1

Provention Bio stock: Frequently Asked Questions

What values and corporate philosophy does Provention Bio represent?

Provention Bio Inc represents a commitment to innovation, integrity, and patient-centricity. As a leading biopharmaceutical company, Provention Bio is focused on developing transformative therapies to intercept and prevent immune-mediated diseases. The company aims to address unmet medical needs, prioritize patient well-being, and improve healthcare outcomes worldwide. With a visionary corporate philosophy, Provention Bio is dedicated to advancing novel treatments through rigorous research, strategic collaborations, and a deep understanding of autoimmune disorders. By prioritizing scientific excellence and patient advocacy, Provention Bio is poised to make a significant impact in the field of immune-mediated diseases.

In which countries and regions is Provention Bio primarily present?

Provention Bio Inc primarily operates in the United States.

What significant milestones has the company Provention Bio achieved?

Provention Bio Inc. has achieved several significant milestones since its establishment. Notably, the company successfully completed a Phase 2B trial for its lead product candidate, PRV-031, in patients with type 1 diabetes. Provention Bio Inc. also received Breakthrough Therapy designation from the U.S. FDA for PRV-031, highlighting its potential to address the unmet medical needs in type 1 diabetes. Additionally, the company entered into a licensing agreement with Janssen Biotech Inc. to develop and commercialize PRV-6527, a potential treatment for Crohn's disease. These achievements demonstrate Provention Bio Inc.'s dedication to developing innovative therapies that offer hope to patients suffering from debilitating diseases.

What is the history and background of the company Provention Bio?

Provention Bio Inc is a biopharmaceutical company specializing in the development of immune-based therapies. Founded in 2016, Provention Bio Inc has emerged as a leader in innovative treatments for autoimmune diseases. The company's focus lies in identifying and advancing therapeutic candidates that target the underlying causes of these diseases. With a strong commitment to research and development, Provention Bio Inc has established strategic partnerships and collaborations to accelerate its pipeline and bring novel therapies to patients. This dedication has positioned Provention Bio Inc as a key player in the field, poised to address unmet medical needs and make a lasting impact.

Who are the main competitors of Provention Bio in the market?

The main competitors of Provention Bio Inc in the market are companies such as Eli Lilly and Company, Novo Nordisk A/S, and Sanofi SA.

In which industries is Provention Bio primarily active?

Provention Bio Inc is primarily active in the biotechnology industry.

What is the business model of Provention Bio?

The business model of Provention Bio Inc. focuses on the development and commercialization of therapeutics and solutions for the prevention and interception of immune-mediated diseases. Provention Bio Inc. primarily targets chronic autoimmune and inflammatory diseases, such as type 1 diabetes, Crohn's disease, and lupus. The company utilizes innovative approaches, including advanced diagnostics, predictive analytics, and precision medicine, to identify individuals at high risk of developing these diseases and intervene early with preventive treatments. Provention Bio Inc. aims to improve patient outcomes and quality of life by effectively managing immune-mediated diseases through their comprehensive approach.

What is the P/E ratio of Provention Bio 2024?

The Provention Bio P/E ratio is -32.05.

What is the P/S ratio of Provention Bio 2024?

The Provention Bio P/S ratio is 14.03.

What is the AlleAktien quality score of Provention Bio?

The AlleAktien quality score for Provention Bio is 3/10.

What is the revenue of Provention Bio 2024?

The expected Provention Bio revenue is 133.08 M USD.

How high is the profit of Provention Bio 2024?

The expected Provention Bio profit is -58.25 M USD.

What is the business model of Provention Bio

Provention Bio Inc is a biopharmaceutical company specializing in the prevention of autoimmune diseases and other chronic illnesses. The company operates in several areas, including clinical research, product development, and partnerships. The clinical research focuses on identifying new therapies and diagnoses for autoimmune diseases such as type 1 diabetes, celiac disease, and lupus. The product development includes the development of preventive therapies for type 1 diabetes and diagnostic tools for autoimmune diseases. Partnerships with universities, bio-pharmaceutical companies, and other academic institutions are also an important part of the company's business model.

What is the Provention Bio dividend?

Provention Bio pays a dividend of 0 USD distributed over payouts per year.

How often does Provention Bio pay dividends?

The dividend cannot currently be calculated for Provention Bio or the company does not pay out a dividend.

What is the Provention Bio ISIN?

The ISIN of Provention Bio is US74374N1028.

What is the Provention Bio WKN?

The WKN of Provention Bio is A2JRLW.

What is the Provention Bio ticker?

The ticker of Provention Bio is PRVB.

How much dividend does Provention Bio pay?

Over the past 12 months, Provention Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Provention Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Provention Bio?

The current dividend yield of Provention Bio is .

When does Provention Bio pay dividends?

Provention Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Provention Bio?

Provention Bio paid dividends every year for the past 0 years.

What is the dividend of Provention Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Provention Bio located?

Provention Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Provention Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Provention Bio from 7/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/4/2024.

When did Provention Bio pay the last dividend?

The last dividend was paid out on 7/4/2024.

What was the dividend of Provention Bio in the year 2023?

In the year 2023, Provention Bio distributed 0 USD as dividends.

In which currency does Provention Bio pay out the dividend?

The dividends of Provention Bio are distributed in USD.

Other fundamentals and analyses of Provention Bio in the deep dive.

Our stock analysis for Provention Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Provention Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.